Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
32
NCT02010567
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
Phase: Phase 1/2
Role: Collaborator
Start: Dec 31, 2013
Completion: Jun 25, 2019